

# A Molecular Signature Predictive of Indolent Prostate C

Science Translational Medicine

5, 202ra122

DOI: [10.1126/scitranslmed.3006408](https://doi.org/10.1126/scitranslmed.3006408)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Copy number alteration burden predicts prostate cancer relapse. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11139-11144.	3.3	299
3	Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British Journal of Cancer, 2014, 111, 1201-1212.	2.9	123
4	Molecular markers to guide primary radical treatment selection in localized prostate cancer. Expert Review of Molecular Diagnostics, 2014, 14, 871-881.	1.5	5
5	Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review. BioMed Research International, 2014, 2014, 1-12.	0.9	41
6	The Thoc1 Ribonucleoprotein and Prostate Cancer Progression. Journal of the National Cancer Institute, 2014, 106, dju306-dju306.	3.0	19
7	Single luminal epithelial progenitors can generate prostate organoids in culture. Nature Cell Biology, 2014, 16, 951-961.	4.6	283
8	FGF23: Mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?. Medical Hypotheses, 2014, 83, 482-487.	0.8	19
9	New concepts concerning prostate cancer screening. Experimental Biology and Medicine, 2014, 239, 793-804.	1.1	3
10	High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecologic Oncology, 2014, 133, 197-204.	0.6	70
11	The prognostic significance of Gleason scores in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 707-713.	0.8	48
12	Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biology of the Cell, 2015, 107, 232-244.	0.7	6
13	Androgen receptor profiling predicts prostate cancer outcome. EMBO Molecular Medicine, 2015, 7, 1450-1464.	3.3	67
14	Nanocytological Field Carcinogenesis Detection to Mitigate Overdiagnosis of Prostate Cancer: A Proof of Concept Study. PLoS ONE, 2015, 10, e0115999.	1.1	27
15	RNA biomarkers to facilitate the identification of aggressive prostate cancer. Molecular Aspects of Medicine, 2015, 45, 37-46.	2.7	16
16	Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Systems Biology, 2015, 9, 55.	3.0	20
17	The biology of castration-resistant prostate cancer. Current Problems in Cancer, 2015, 39, 17-28.	1.0	22
18	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	0.9	166
19	Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine, 2015, 2, 1133-1144.	2.7	260

#	ARTICLE	IF	CITATIONS
20	BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. <i>Nature Genetics</i> , 2015, 47, 22-30.	9.4	141
21	Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. <i>Oncogene</i> , 2015, 34, 2094-2102.	2.6	72
22	The genetic classification of prostate cancer: whatâ€™s on the horizon?. <i>Future Oncology</i> , 2016, 12, 729-733.	1.1	5
23	The role of chemotherapy and new targeted agents in the management of primary prostate cancer. <i>Journal of Clinical Urology</i> , 2016, 9, 30-37.	0.1	2
24	Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1395-1401.	2.3	21
25	Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes. <i>Cancer &amp; Metabolism</i> , 2016, 4, 8.	2.4	17
26	Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. <i>Nature Communications</i> , 2016, 7, 10798.	5.8	166
27	Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis. <i>Scientific Reports</i> , 2016, 6, 22051.	1.6	19
28	Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation. <i>Science</i> , 2016, 352, 1576-1580.	6.0	80
29	Integrated analysis of the prostate cancer smallâ€nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. <i>Molecular Oncology</i> , 2016, 10, 693-703.	2.1	48
30	<i>Atg7</i> cooperates with <i>Pten</i> loss to drive prostate cancer tumor growth. <i>Genes and Development</i> , 2016, 30, 399-407.	2.7	97
31	Optimizing mouse models for precision cancer prevention. <i>Nature Reviews Cancer</i> , 2016, 16, 187-196.	12.8	59
32	Use of two gene panels for prostate cancer diagnosis and patient risk stratification. <i>Tumor Biology</i> , 2016, 37, 10115-10122.	0.8	9
33	Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 40-45.	2.0	6
34	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 157-165.	0.9	206
36	Prostate cancer, PI3K, PTEN and prognosis. <i>Clinical Science</i> , 2017, 131, 197-210.	1.8	146
37	Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 24-32.	0.3	1
38	Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5 $\alpha$ -reductase Inhibition. <i>European Urology</i> , 2017, 72, 499-506.	0.9	16

#	ARTICLE	IF	CITATIONS
39	The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 385-400.	1.6	18
40	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	3.2	87
41	Machine learning models to search relevant genetic signatures in clinical context. , 2017, , .		3
42	Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate Cancer. <i>Stem Cells Translational Medicine</i> , 2017, 6, 748-760.	1.6	19
43	Predictive models and risk of biopsy progression in active surveillance patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 37.e1-37.e8.	0.8	4
44	Combinatorial Ranking of Gene Sets to Predict Disease Relapse: The Retinoic Acid Pathway in Early Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 30.	1.3	5
45	Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness. <i>PLoS ONE</i> , 2017, 12, e0185447.	1.1	11
46	Improvement in prediction of prostate cancer prognosis with somatic mutational signatures. <i>Journal of Cancer</i> , 2017, 8, 3261-3267.	1.2	33
47	Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers. <i>International Journal of Molecular Sciences</i> , 2017, 18, 740.	1.8	27
48	Prostate Cancer Molecular Prognosis. <i>Molecular Pathology Library</i> , 2018, , 503-522.	0.1	2
49	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 182-189.	2.7	132
50	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 103-113.	1.3	20
51	Logic Learning Machine and standard supervised methods for Hodgkin's lymphoma prognosis using gene expression data and clinical variables. <i>Health Informatics Journal</i> , 2018, 24, 54-65.	1.1	18
52	Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention. <i>Molecular Cancer Research</i> , 2018, 16, 115-123.	1.5	12
53	Exploring the transcriptome of hormone-naïve multifocal prostate cancer and matched lymph node metastases. <i>British Journal of Cancer</i> , 2018, 119, 1527-1537.	2.9	10
54	KLF4, A Gene Regulating Prostate Stem Cell Homeostasis, Is a Barrier to Malignant Progression and Predictor of Good Prognosis in Prostate Cancer. <i>Cell Reports</i> , 2018, 25, 3006-3020.e7.	2.9	22
55	Cooperation of loss of <i>NKX3.1</i> and inflammation in prostate cancer initiation. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	30
56	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	2.7	434

#	ARTICLE	IF	CITATIONS
57	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. <i>European Urology Oncology</i> , 2018, 1, 268-275.	2.6	5
58	Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. <i>Annals of Oncology</i> , 2018, 29, 1814-1821.	0.6	35
59	Computer-aided diagnosis of clinically significant prostate cancer from MRI images using sparse autoencoder and random forest classifier. <i>Biocybernetics and Biomedical Engineering</i> , 2018, 38, 733-744.	3.3	33
60	Computer-aided classification of prostate cancer grade groups from MRI images using texture features and stacked sparse autoencoder. <i>Computerized Medical Imaging and Graphics</i> , 2018, 69, 60-68.	3.5	62
61	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 645-655.	1.5	20
62	Computer-aided grading of prostate cancer from MRI images using Convolutional Neural Networks. <i>Journal of Intelligent and Fuzzy Systems</i> , 2019, 36, 2015-2024.	0.8	18
63	TRIM24 as an independent prognostic biomarker for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 576.e1-576.e10.	0.8	18
64	A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer. <i>BMC Cancer</i> , 2019, 19, 423.	1.1	11
65	Cancer overdiagnosis: a biological challenge and clinical dilemma. <i>Nature Reviews Cancer</i> , 2019, 19, 349-358.	12.8	220
66	Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. <i>Nature Reviews Urology</i> , 2019, 16, 302-317.	1.9	86
67	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. <i>Endocrine-Related Cancer</i> , 2019, 26, R31-R52.	1.6	49
68	Mechanisms of PTEN loss in cancer: It's all about diversity. <i>Seminars in Cancer Biology</i> , 2019, 59, 66-79.	4.3	214
69	MiR-644a Disrupts Oncogenic Transformation and Warburg Effect by Direct Modulation of Multiple Genes of Tumor-Promoting Pathways. <i>Cancer Research</i> , 2019, 79, 1844-1856.	0.4	35
70	Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer. <i>BMC Urology</i> , 2019, 19, 4.	0.6	8
71	Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030528.	2.9	36
72	Role of the DNA damage response in prostate cancer formation, progression and treatment. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 24-37.	2.0	37
73	Dual and multi-targeted nanoparticles for site-specific brain drug delivery. <i>Journal of Controlled Release</i> , 2020, 317, 195-215.	4.8	72
74	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3637-3647.	3.3	17

#	ARTICLE	IF	CITATIONS
75	Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression. <i>Genes</i> , 2020, 11, 802.	1.0	8
76	Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 3808-3818.	0.7	10
77	NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation. <i>Cancer Discovery</i> , 2021, 11, 2316-2333.	7.7	25
79	Limitations of Explainability for Established Prognostic Biomarkers of Prostate Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 649429.	1.1	5
80	Immunopathologic Assessment of PTEN Expression. <i>Methods in Molecular Biology</i> , 2016, 1388, 23-37.	0.4	8
81	Gleason 6 Tumors Should Still Be Labeled as Cancer. <i>Current Clinical Urology</i> , 2018, , 41-52.	0.0	1
82	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 4492-4505.	3.9	250
83	Computational Reconstruction of NF $\kappa$ B Pathway Interaction Mechanisms during Prostate Cancer. <i>PLoS Computational Biology</i> , 2016, 12, e1004820.	1.5	27
84	Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and miR-186 expression: Novel mechanism of VEGF modulation in prostate cancer. <i>Oncotarget</i> , 2016, 7, 44350-44364.	0.8	24
85	A four gene signature predictive of recurrent prostate cancer. <i>Oncotarget</i> , 2017, 8, 3430-3440.	0.8	14
86	Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia. <i>Oncotarget</i> , 2017, 8, 76987-76999.	0.8	14
87	Molecular pathways and targets in prostate cancer. <i>Oncotarget</i> , 2014, 5, 7217-7259.	0.8	84
88	Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. <i>Oncotarget</i> , 2016, 7, 5273-5288.	0.8	60
89	Prostate cancer: unmet clinical needs and RAD9 as a candidate biomarker for patient management. <i>Translational Cancer Research</i> , 2018, 7, S651-S661.	0.4	8
90	Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2020, 11, 43-52.	0.9	12
91	Tools to identify the men with prostate cancer most appropriate for active surveillance?. <i>Asian Journal of Andrology</i> , 2014, 16, 97.	0.8	0
92	Gene Expression Analysis. <i>Molecular Pathology Library</i> , 2018, , 153-167.	0.1	0
94	Unifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer Management. <i>Springer Theses</i> , 2019, , 1-29.	0.0	0

#	ARTICLE	IF	CITATIONS
96	A value predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response. <i>NAR Cancer</i> , 2022, 4, zcac010.	1.6	7
97	A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis. <i>Production and Operations Management</i> , 2022, 31, 2361-2378.	2.1	5
98	Patterns of indolence in prostate cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 351.	0.8	5
99	Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts. <i>Cancer Research</i> , 2022, 82, 1832-1843.	0.4	13
100	<i>MCAM</i> is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24214.	0.9	5
101	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 513-523.	2.0	2
102	Correlation between stage of prostate cancer and tyrosine and tryptophan in urine samples measured electrochemically. <i>Analytical Biochemistry</i> , 2022, 649, 114698.	1.1	5
103	Scaffold protein MAPK8IP2 expression is a robust prognostic factor in prostate cancer associated with AR signaling activity. <i>Asian Journal of Andrology</i> , 2023, 25, 198.	0.8	5
104	Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 255-275.	0.8	1
106	Immunoarray Measurements of Parathyroid Hormone-Related Peptides Combined with Other Biomarkers to Diagnose Aggressive Prostate Cancer. <i>Analytical Chemistry</i> , 2022, 94, 12788-12797.	3.2	3
107	Dramatic impact of partial loss of PTEN function on tumorigenesis and progression of prostate cancer. , 2023, , 339-356.		0
112	From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine. <i>Health Information Science and Systems</i> , 2024, 12, .	3.4	0